ALDH1A2

Across TCGA pan-cancer cohorts, ALDH1A2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALDH1A2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALDH1A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ALDH1A2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, ESCA, and UCEC are the cancer types where ALDH1A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.563	0.835	<.001	22	view →
ESCA	OS	Median	All	0.176	0.700	.006	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SKCM	OS	Median	All	0.606	0.302	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ALDH1A2–LUAD (OS)

Open the LUAD breakdown →